{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:19:54Z","timestamp":1772810394305,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.clinthera.2009.02.008","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T11:45:18Z","timestamp":1237463118000},"page":"386-398","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation"],"prefix":"10.1016","volume":"31","author":[{"given":"Petro E.","family":"Petrides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Linkesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Krumpl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Sch\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Widmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.02.008_bib1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1517\/14656566.5.8.1781","article-title":"Anagrelide: A decade of clinical experience with its use for the treatment of primary thrombocythaemia","volume":"5","author":"Petrides","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2009.02.008_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/14737140.9.1.37","article-title":"Anagrelide: 20 Years later","volume":"9","author":"Emadi","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clinthera.2009.02.008_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/clpt.1981.52","article-title":"Disposition of anagrelide, an inhibitor of platelet aggregation","volume":"29","author":"Gaver","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2009.02.008_bib4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.bjp.0706341","article-title":"Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures","volume":"146","author":"Wang","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2009.02.008_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.exphem.2005.09.009","article-title":"A preliminary investigation into the action of anagrelide: Thrombopoietinc-Mpl receptor interactions","volume":"34","author":"McCarty","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clinthera.2009.02.008_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.moh.0000219660.03657.4b","article-title":"Transcriptional regulation of megakaryopoiesis: Thrombopoietin signaling and nuclear factors","volume":"13","author":"Kirito","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clinthera.2009.02.008_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2009.02.008_bib8","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","article-title":"Anagrelide for thrombocytosis in myeloproliferative disorders: A prospective study to assess efficacy and adverse event profile","volume":"101","author":"Steurer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2009.02.008_bib9","first-page":"520","article-title":"Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders","volume":"89","author":"Birgegard","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2009.02.008_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2009.02.008_bib11","article-title":"Final results of the ANAHYDRET-Study: Noninferiority of anagrelide compared to hydroxyurea in newly diagnosed WHO-essential thrombocythemia patients","volume":"112","author":"Gisslinger","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clinthera.2009.02.008_bib12","series-title":"Agrylin (anagrelide) capsules [product information]","year":"1997"},{"key":"10.1016\/j.clinthera.2009.02.008_bib13","series-title":"Xagrid (anagrelide) capsules [product information]","year":"2005"},{"key":"10.1016\/j.clinthera.2009.02.008_bib14","series-title":"Thromboreductin (anagrelide) capsules [product information]","year":"2008"},{"key":"10.1016\/j.clinthera.2009.02.008_bib15","unstructured":"Note for Guidance on Good Clinical Practice. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit (CPMP\/ICH\/135\/95, January 17, 1997)."},{"key":"10.1016\/j.clinthera.2009.02.008_bib16","series-title":"World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects","year":"2000"},{"key":"10.1016\/j.clinthera.2009.02.008_bib17_1","unstructured":"Note for Guidance for the Investigation of Bioavailability and Bioequivalence (CPMP\/EWP\/QWP\/1401\/98 July 2001) [European Medicines Agency Web site]"},{"key":"10.1016\/j.clinthera.2009.02.008_bib18_1","unstructured":"Note for Guidance on Validation of Analytical Procedures: Methodology (CPMP\/ICH\/281\/95) [European Medicines Agency Web site]"},{"key":"10.1016\/j.clinthera.2009.02.008_bib19","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"Chow","year":"1992"},{"key":"10.1016\/j.clinthera.2009.02.008_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2009.02.008_bib21_1","unstructured":"Note for Guidance on Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP\/ICH\/377\/95)"},{"key":"10.1016\/j.clinthera.2009.02.008_bib22","series-title":"European Pharmacopoiea","year":"2008"},{"key":"10.1016\/j.clinthera.2009.02.008_bib23","first-page":"339","article-title":"Diagnosis and classification of the polycythemias","volume":"12","author":"Berlin","year":"1975","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clinthera.2009.02.008_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0301-472X(02)00870-6","article-title":"Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)?","volume":"30","author":"Erusalimsky","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clinthera.2009.02.008_bib25","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/0006-2952(88)90054-8","article-title":"Anagrelide: A potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity","volume":"37","author":"Gillespie","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2009.02.008_bib26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1172\/JCI117683","article-title":"cGMP inhibition of heart phosphodiesterase: Is it clinically relevant?","volume":"95","author":"Beavo","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2009.02.008_bib27","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1592\/phco.20.15.1224.34591","article-title":"Anagrelide-induced cardiomyopathy","volume":"20","author":"James","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2009.02.008_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-143-4-200508160-00020","article-title":"High-output heart failure associated with anagrelide therapy for essential thrombocytosis","volume":"143","author":"Engel","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2009.02.008_bib29","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T01:52:17Z","timestamp":1545357137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0149291809000514"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.02.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}